Skip to NavigationSkip to content

Pfizer announces strong Phase III results for atopic dermatitis drug

Published on 14/07/16 at 09:18am

Pfizer (NYSE: PFE) has announced positive results from two pivotal Phase III studies for crisaborole in the treatment of mild to moderate atopic dermatitis.

The company acquired the investigational compound as part of their $5.2 billion takeover of Anacor Pharmaceuticals in May. Crisaborole is a differentiated non-steroidal topical PED4 inhibitor with anti-inflammatory properties. At the time of the takeover, Pfizer indicated its peak sales could have the potential to reach or exceed $2 billion.

In these Phase III trials, the results of which were published in the Journal of the American Academy of Dermatology, the drug achieved statistically significant results on primary and secondary endpoints, including patient’s investigator static global assessment (ISGA) score, and changes in baseline of dermatitis rating.

Amy Paller, professor of paediatrics at Northwestern University, says: “Atopic dermatitis, or eczema, is a chronic, inflammatory skin disease that affects millions of children and adults. There have been no new therapies approved in the US for people with atopic dermatitis in the last 15 years. The results seen in these pivotal Phase III studies demonstrated that crisaborole, if approved, could be a meaningful treatment option for patients with mild to moderate atopic dermatitis.”

Sean Murray

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches